Where is PhaseBio’s corporate headquarters?
PhaseBio is headquartered at 1 Great Valley Parkway, Suite 30, Malvern, Pennsylvania 19355. PhaseBio also maintains an administrative office at 11260 El Camino Real Suite 100, San Diego, California 92130.
Where is PhaseBio incorporated?
PhaseBio is incorporated in Delaware.
What is PhaseBio’s fiscal year?
PhaseBio’s fiscal year is January 1 to December 31.
How is PhaseBio’s stock traded and when did PhaseBio go public?
PhaseBio’s common stock is traded under the ticker symbol “PHAS” on the Nasdaq Global Market. First trading day was on October 18, 2018.
How can I purchase or sell shares of PhaseBio’s common stock?
Shares can be purchased through a licensed securities broker. PhaseBio does not have a direct stock purchase program.
Does PhaseBio pay dividends?
PhaseBio has never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future.
Who is PhaseBio’s transfer agent, and how do I contact them?
Computershare. They can be contacted at https://www-us.computershare.com/Investor/Contact.
Who do I contact regarding lost stock certificates, address changes and changes of ownership or name in which shares are held?
Contact our transfer agent, Computershare at https://www-us.computershare.com/Investor/Contact
Who is PhaseBio’s independent registered public accounting firm?
KPMG LLP is PhaseBio’s independent registered public accounting firm.
Who is PhaseBio’s legal counsel?
Cooley LLP is PhaseBio’s legal counsel.
Where can I get the latest corporate news release?
PhaseBio’s press release archives can be viewed at: Press Releases.
How can I view documents that PhaseBio has filed with the Securities and Exchange Commission (SEC), including Forms 10-K and 10-Q?
How do I contact PhaseBio with additional questions?
Please use the investor inquiry form to submit queries to PhaseBio’s investor relations department.